ESR1 and cervical carcinoma: Although the relationship between estradiol (E2) replacement or selective ER modulator (SERM) treatment and cervical cancer is contentious [24], the E2-ERα and progesterone–progesterone receptor (P4-PR) signaling pathways may be implicated in the progression and/or development of cervical cancer.